Fuan Pharmaceutical (300194.SZ): Oncology adjuvant drugs such as Ondansetron Hydrochloride Injection have been included in the centralized procurement program and successfully selected.

On May 7, GENOR reports that Fuan Pharmaceuticals (300194.SZ) stated on the investor interaction platform that its anti-tumor adjuvant drugs, including Ondansetron Hydrochloride Injection and Granisetron Hydrochloride Injection, have been included in centralized procurement and selected.

Gelonghui FinanceMay 7 09:17

Fuan Pharmaceutical's net profit attributable to shareholders in 2025 was RMB 0.77 billion, representing a year-on-year decrease of 72.49%. The company reported a single-quarter loss of RMB 0.89 billion in the fourth quarter, while cash flow grew against

In 2025, the company's revenue and profit both declined, with net profit attributable to shareholders dropping by 72.49% year-over-year, turning to a loss in the fourth quarter. Pharmaceuticals and active pharmaceutical ingredients collectively contributed 96.03% of total revenue, reflecting ongoing structural optimization but weakened overall improvement due to volume contraction. Net operating cash flow amounted to 312 million yuan, registering a counter-trend growth of 2.88%, demonstrating resilience in core business receivables.

lanjinger.comApr 27 15:26

Fuan Pharmaceutical: First Quarter Report 2026

SZSIApr 27 00:00 · Announcements

Fuan Pharmaceutical: Annual Report 2025

SZSIApr 27 00:00 · Announcements

Fuan Pharmaceutical: Summary of the Annual Report for 2025

SZSIApr 27 00:00 · Announcements

Express News | Fu'an Pharmaceutical: Subsidiary receives drug registration certificate for Morpholine Nitroimidazole Sodium Chloride Injection.

BreakingsApr 13 15:41